Áttétes emlőrák: vizsgálatok itt: Kanada

In Kanada 30 Also abroad 611

30 trials · From ClinicalTrials.gov, checked 2026. november 10.. Ask the study team whether a trial fits you.

2. fázisTaking people
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Where
Toronto
Életkor
18 év and over
People
120 worldwide
Run by
ALX Oncology Inc.
See details and how to joinNCT07007559
3. fázisTaking people
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Where
Brampton, Montreal, Ottawa, Saskatoon, Toronto
Életkor
18 év and over
People
540 worldwide
Run by
Relay Therapeutics, Inc.
See details and how to joinNCT06982521 · EU 2025-523083-21-00
2/3. fázisTaking people
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
Where
Greenfield Park, Montreal, Ottawa, Québec, Toronto
Életkor
18 év and over
People
650 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07413939 · EU 2025-524498-17-00
3. fázisTaking people
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Where
Calgary, Edmonton, Moncton, Montreal, Ottawa, Saint-Jérôme, Sault Ste. Marie, Toronto, Winnipeg
Életkor
18 év and over
People
450 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06790693 · EU 2024-516162-11-00
3. fázisTaking people
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Where
Hamilton, Québec, Toronto, Vancouver
Életkor
18 év and over
People
800 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07174336 · EU 2025-522791-92-00
3. fázisTaking people
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Where
Moncton, Montreal, Saskatoon, Toronto
Életkor
18 év and over
People
1000 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07060807 · EU 2025-520582-51-00
2. fázisTaking people
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Where
Chicoutimi, Montreal, Ottawa, Toronto
Életkor
18 év and over
People
80 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07405801 · EU 2025-523013-28-00
1. fázisTaking people
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
Where
Toronto
Életkor
18 év and over
People
194 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07604571
3. fázisTaking people
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Where
Greenfield Park, Montreal, Saskatoon, Toronto
Életkor
18 év and over
People
788 worldwide
Run by
AstraZeneca
See details and how to joinNCT06380751 · EU 2023-504180-16-00
3. fázisTaking people
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Where
Montreal, Ottawa, Saguenay, Toronto
Életkor
18 év and over
People
600 worldwide
Run by
LeonaBio
See details and how to joinNCT05696626 · EU 2023-503708-10-00
3. fázisTaking people
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Where
Calgary, Edmonton, Hamilton, Moncton, Montreal, Ottawa, Vancouver
Életkor
18 év and over
People
420 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05646862 · EU 2022-502322-41-00
1/2. fázisTaking people
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Where
Kingston, Montreal, Toronto
Életkor
18 év and over
People
181 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06686394
3. fázisTaking people
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Where
Edmonton, Montreal, Ottawa, Québec, Toronto
Életkor
18 év and over
People
400 worldwide
Run by
Pfizer
See details and how to joinNCT07062965 · EU 2025-520566-22-00
3. fázisTaking people
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Where
Calgary, Moncton, Montreal, Québec, Regina, St. John's, Toronto
Életkor
18 év and over
People
230 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05894239 · EU 2022-502046-28-00
1/2. fázisTaking people
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Where
Chicoutimi, London, Toronto, Vancouver
Életkor
18 év and over
People
380 worldwide
Run by
BioNTech SE
See details and how to joinNCT06827236 · EU 2024-517979-20-00
3. fázisTaking people
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Where
Montreal, Newmarket, Québec, Rimouski, Surrey, Toronto
Életkor
18 év and over
People
1200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06312176 · EU 2023-504918-29-00
1/2. fázisTaking people
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Where
Québec, Toronto, Victoria
People
64 worldwide
Run by
RayzeBio, Inc.
See details and how to joinNCT06590857
2. fázisTaking people
First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.
Where
Vancouver
Életkor
18 év and over
People
24
Run by
Nathalie Levasseur
See details and how to joinNCT07299409
3. fázisTaking people
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Where
Greenfield Park, Toronto
Életkor
18 év and over
People
1000 worldwide
Run by
Olema Pharmaceuticals, Inc.
See details and how to joinNCT07085767 · EU 2025-522873-12-00
No phaseTaking people
EORTC Metastatic Breast Cancer Module Development
Where
Montreal, Toronto
Életkor
18 év and over
People
568 worldwide
Run by
University of Leeds
See details and how to joinNCT07806266
1/2. fázisTaking people
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Where
Montreal, Toronto
Életkor
18 év to 100 év
People
280 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00
4. fázisTaking people
Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers
Where
Kitchener, Ottawa, Saskatoon
Életkor
18 év and over
People
50
Run by
Ottawa Hospital Research Institute
See details and how to joinNCT07252726
2. fázisTaking people
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
Where
Kelowna, Montreal, Toronto
Életkor
18 év and over
People
37 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT04641247 · EU 2023-506618-29-00
2. fázisTaking people
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Where
Calgary, Halifax, Hamilton, Kelowna, Kingston, Montreal, Ottawa, Toronto, Vancouver
People
484
Run by
Canadian Cancer Trials Group
See details and how to joinNCT05601440
1/2. fázisTaking people
HER2-PET Imaging in HER2-low Breast Cancers
Where
Sherbrooke
Életkor
18 év and over
People
40
Run by
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
See details and how to joinNCT06732336